Results 41 to 50 of about 754,759 (237)
Human Vaccines & Immunotherapeutics, 2021 In 2019, Bangladesh has grappled with a record-breaking surge in dengue fever, experiencing the highest number of dengue cases since the year 2000. Together, the intensification of dengue fever combined with a lack of dengue vaccines and appropriate ...
K M Ariful Kabir +2 more
doaj +1 more source
Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.
Cell Host and Microbe, 2021 More than 390 million human dengue virus (DENV) infections occur each year, worldwide. Dengvaxia, a live-virus tetravalent vaccine from Sanofi Pasteur, was recently approved for human clinical use, although vaccine performance against the four DENV ...
David R. Martinez +2 more
semanticscholar +1 more source
Prospects for dengue vaccines for travelers. [PDF]
Clin Exp Vaccine Res, 2016 Travel-acquired dengue cases have been increasing as the overall global dengue burden has expanded. In Korea, imported dengue cases have been reported since 2000 when it first became a notifiable disease. During the first four months of 2016, three times
Lim SK +4 more
europepmc +2 more sources
Vaccine development for mosquito-borne viral diseases
Frontiers in Immunology, 2023 Mosquito-borne viral diseases are a group of viral illnesses that are predominantly transmitted by mosquitoes, including viruses from the Togaviridae and Flaviviridae families.
Zhiwei Huang +7 more
doaj +1 more source
Frontiers in Immunology, 2021 The four serotypes of Dengue virus (DENV1-4) are arboviruses (arthropod-borne viruses) that belong to the Flavivirus genus, Flaviviridae family. They are the causative agents of an infectious disease called dengue, an important global public health ...
Josilene Ramos Pinheiro +13 more
doaj +1 more source
Archives of the Balkan Medical Union, 2022 Dengue is estimated to be the most common mosquito-borne disease globally, affecting mainly tropical and subtropical countries. It has been identified as a disease of the future, due to persistent trends in urbanization of societies, scarce water resources and changes in the environment. The four dengue virus serotypes cause from the usual mild illness
Radka KOMITOV +3 more
openaire +2 more sources
Dengue vaccine acceptability before and after the availability of COVID-19 vaccines in Puerto Rico
Vaccine, 2023 Dengue is a growing public health threat, causing approximately 400 million infections annually. In June 2021, the Advisory Committee on Immunization Practices recommended the first dengue vaccine (CYD-TDV) for children aged 9–16 years with a previous ...
Dania M Rodríguez +8 more
semanticscholar +1 more source
Dengue virus infection – a review of pathogenesis, vaccines, diagnosis and therapy
Virus Research, 2022 Highlights • Reviews on unsolved issues of DENV from different perspectives such as the effect of antibody dependent enhancement, immune escape and limitations of commercial diagnostic kits.• Case studies on variety of potential therapeutic candidates ...
B. H. Kok +5 more
semanticscholar +1 more source
Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. [PDF]
Vaccine, 2018 Licensing and decisions on public health use of a vaccine rely on a robust clinical development program that permits a risk-benefit assessment of the product in the target population.
Vannice KS +14 more
europepmc +2 more sources
, 2010 INTRODUCTION: Dengue is a vector-borne viral infection that endangers an estimated 2.5 billion people. Disease caused by dengue ranges from a relatively minor febrile illness to a life-threatening condition characterized by extensive capillary leak.
Whitehorn, J +6 more
core +1 more source